Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Common Stock of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2021.

04/21/2021 EDT

Certain Common Stock of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2021. These Common Stock will be under lockup for 91 days starting from 20-JAN-2021 to 21-APR-2021. Details: Executive officers and directors have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 90 days after the date of this prospectus supplement without first obtaining the written consent of BofA Securities, Inc. and Jefferies LLC.


© S&P Capital IQ 2021
All news about INOVIO PHARMACEUTICALS, INC.
09/10INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Un..
MT
09/01INOVIO PHARMACEUTICALS : to Present at Upcoming Investor Conferences in Septembe..
PR
08/26INOVIO PHARMACEUTICALS : Receives Authorization From Brazil Regulator to Start P..
MT
08/26INOVIO PHARMACEUTICALS : Receives Authorization to Conduct Phase 3 Efficacy Tria..
PR
08/26INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-..
CI
08/09INOVIO PHARMACEUTICALS : focused on launching global COVID-19 vaccine trial next..
RE
08/09INOVIO PHARMACEUTICALS : focused on launching global COVID-19 vaccine trial next..
RE
08/09INOVIO : Q2 Earnings Snapshot
AQ
08/09INOVIO PHARMACEUTICALS : Reports Narrower Q2 Loss on Higher Revenue
MT
08/09INOVIO PHARMACEUTICALS : Earnings Flash (INO) INOVIO PHARMACEUTICALS Posts Q2 Re..
MT
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 4,71 M - -
Net income 2021 -272 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,26x
Yield 2021 -
Capitalization 1 712 M 1 712 M -
Capi. / Sales 2021 364x
Capi. / Sales 2022 17,3x
Nbr of Employees 262
Free-Float 98,3%
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 8,14 $
Average target price 13,22 $
Spread / Average Target 62,4%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-8.02%1 712
MODERNA, INC.311.65%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.07%49 407
CELLTRION, INC.-23.26%31 021
SEAGEN INC.-10.81%27 940